IN THE NEWS
Mayne Pharma Announces Strategic investment in US Facilities
Mayne Pharma is an ASX-listed specialty pharmaceutical company focused on commercializing branded and generic pharmaceuticals. Mayne Pharma also provides contract development and manufacturing services to clients worldwide...
To improve patient access to life-enhancing prescription medications, Mayne Pharma offers a robust portfolio of branded and generic drugs in multiple therapeutic areas, including women's health, oncology, dermatology and cardiology.
NEWS AND EVENTS
Nextstellis® Oral Contraceptive Now Available in the United States Mayne Pharma Expands Australian Dermatology Portfolio Nextstellis® Receives FDA Marketing Exclusivity and Phase III Data Published U.S. FDA APPROVES NEXTSTELLIS ®, NEW ORAL CONTRACEPTIVE FDA approval of novel oral contraceptive NEXTSTELLIS®
One of the keys to Mayne Pharma’s success has been the implementation of strategic partnerships and alliances by licensing products that we are able to market in the USA or Australia and to develop partnerships for the global marketing of products developed by Mayne Pharma...
Mayne Pharma has a 40-year track record of innovation and success developing new oral drug delivery systems and these technologies have been successfully commercialized in numerous products that continue to be marketed around the world...
|Market Cap:||52 Week: -|